机译:P2.02-041在IIIA期/ N2非小细胞肺癌中同时化疗和高剂量(61GY)辐射后手术切除的影响
Department of Thoracic Surgery Istanbul University Cerrahpasa Medical Faculty;
Department of Thoracic Surgery Istanbul University Cerrahpasa Medical School;
Department of Thoracic Surgery Istanbul University Cerrahpasa Medical School;
Department of Thoracic Surgery Istanbul University Cerrahpasa Medical School;
Department of Medical Oncology Istanbul University Cerrahpasa Medical School;
Istanbul University department Ofradiation Oncology Fatih Istanbul University department;
Department of Pulmonary Medicine Istanbul University Cerrahpasa Medical School;
Department of Pulmonary Medicine Istanbul University Cerrahpasa Medical School;
Department of Thoracic Surgery Istanbul University Cerrahpasa Medical Faculty;
机译:P2.02-041在IIIA期/ N2非小细胞肺癌中同时化疗和高剂量(61GY)辐射后手术切除的影响
机译:不可切除的IIIA期和IIIB期非小细胞肺癌患者先用卡铂,伊立替康和紫杉醇诱导化疗,然后进行高剂量三维保形胸放疗(74 Gy)并用卡铂,紫杉醇和吉非替尼。
机译:使用1.2的脊髓剂量>或= 50.4 Gy后,无胸廓辐射性脊髓炎。 Gy b.i.d.超分割放疗联合或不联合化疗治疗III期非小细胞肺癌患者的临床分馏。
机译:细胞因子诱导的杀伤细胞输注结合化学疗法和消积汤治疗IIIB / IV期非小细胞肺癌的临床疗效
机译:Erlotinib单疗法和蛋白质在先前未处理阶段I-IIIA非小细胞肺癌中的研究
机译:在手术切除之前接受新辅助化学疗法和/或放疗的IIIA期(N2)非小细胞肺癌患者有生存益处
机译:P2-189:经病理证实的N2期(pN2)IIIA期非小细胞肺癌(NSCLC)的新辅助每周紫杉醇/顺铂化疗(WPC)并发胸腔放射(TR),然后进行手术切除(S):II期研究